Evidence map›Paper›PMID 19389159›Full record

ArticleBritish journal of pharmacology2009

Characterization of hadrucalcin, a peptide from Hadrurus gertschi scorpion venom with pharmacological activity on ryanodine receptors.

Elisabeth F Schwartz, E Michelle Capes, Elia Diego-García, Fernando Z Zamudio, Oscar Fuentes, Lourival D Possani, Héctor H Valdivia

Open access · bronzeAbstract read
In one paragraph

Article in British journal of pharmacology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 64 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Australian ScorpionBiomolecules · 2020
    Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 4 countries.

Elisabeth F SchwartzDepartment of Physiological Sciences, Institute of Biological Sciences, University of Brasilia, Brasilia, Brazil.
E Michelle Capes
Elia Diego-García
Fernando Z Zamudio
Oscar Fuentes
Lourival D Possani
Héctor H Valdivia
Universidad Nacional Autónoma de México · MXUniversity of Wisconsin–Madison · USUniversidad Adventista de Chile · CL

Funding

Ryanodine Receptors, Calcium-dependent Arrhythmias & HCMR01HL055438 · NHLBI · UNIVERSITY OF WISCONSIN-MADISON · PI VALDIVIA, HECTOR H · 1996 to 2023
$8.0M
Modulation of Cardiac E-C Coupling by SorcinR01HL076826 · NHLBI · UNIVERSITY OF WISCONSIN-MADISON · PI VALDIVIA, HECTOR H · 2004 to 2008
$1.8M
NHLBI NIH HHS HL-55438NHLBI NIH HHS HL-76826NHLBI NIH HHS R01 HL055438NHLBI NIH HHS R01 HL076826
6 · The paper itself

Abstract

background and purposeMembers of the calcin family, presently including imperatoxin A, maurocalcin, opicalcins and hemicalcin, are basic, 33-mer peptide activators of ryanodine receptors (RyRs), the calcium channels of the sarcoplasmic reticulum (SR) that provide the majority of calcium for muscle contraction. Here we describe hadrucalcin, a novel member of this family. EXPERIMENTAL APPROACH: Hadrucalcin was isolated from the venom of Hadrurus gertschi. Amino acid sequence and mass were determined by Edman degradation and mass spectrometry respectively. A cDNA library was constructed to generate clones for DNA sequence determination. Biological activity of native toxin was confirmed with [(3)H]ryanodine binding, by using SR vesicles from cardiac and skeletal muscle, and with single skeletal (RyR1) and cardiac (RyR2) channels reconstituted in lipid bilayers. Hadrucalcin was applied to intact ventricular myocytes to investigate effects on calcium transients. The secondary structure of hadrucalcin was computer-modelled by using atomic coordinates from maurocalcin, a structurally similar peptide. KEY

resultsHadrucalcin is distinguished from previously described congeners by two additional amino acids in its primary sequence and the lack of prominent amphipathicity. Hadrucalcin activated RyRs with high affinity (EC(50)= 37 nmol.L(-1)), induced a long-lasting subconductance state on RyR1 and RyR2, and rapidly (lag time approximately 2 s) penetrated ventricular cardiomyocytes, eliciting discharge of internal calcium stores and spontaneous contractions. CONCLUSIONS AND IMPLICATIONS: Hadrucalcin is a cell-permeant, powerful activator of RyRs, which has translational potential for targeted delivery of drugs to RyR as novel therapeutic intervention in arrhythmogenic disease.

Indexed as

Amino Acid SequenceAnimalsBase SequenceCalciumCalcium Channel AgonistsCell Membrane PermeabilityDogsFemaleMaleMiceModels, MolecularMolecular Sequence DataMyocytes, CardiacPeptidesProtein Structure, SecondaryRabbitsCalciumCalcium Channel Agonistshadrucalcin protein, Hadrurus gertschiPeptidesRyanodine Receptor Calcium Release ChannelScorpion Venoms

Identifiers

PMID19389159
PMCPMC2707986
OpenAlexW1569967926

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.